TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Nordic Drugs AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
235,956
|
226,707
|
200,521 |
| Financial expenses |
933
|
9
|
50 |
| Earnings before taxes |
24,629
|
10,011
|
-1,985 |
| EBITDA |
24,787
|
9,471
|
-2,621 |
| Total assets |
120,905
|
114,305
|
92,950 |
| Current assets |
120,561
|
113,565
|
91,339 |
| Current liabilities |
36,012
|
45,298
|
30,683 |
| Equity capital |
82,760
|
65,757
|
59,049 |
| - share capital |
12,989
|
13,433
|
13,365 |
| Employees (average) |
25
|
25
|
26 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
68.5%
|
57.5%
|
63.5% |
| Turnover per employee |
9,438
|
9,068
|
7,712 |
| Profit as a percentage of turnover |
10.4%
|
4.4%
|
-1.0% |
| Return on assets (ROA) |
21.1%
|
8.8%
|
-2.1% |
| Current ratio |
334.8%
|
250.7%
|
297.7% |
| Return on equity (ROE) |
29.8%
|
15.2%
|
-3.4% |
| Change turnover |
16,748
|
25,154
|
40,117 |
| Change turnover % |
8%
|
12%
|
25% |
| Chg. No. of employees |
0
|
-1
|
0 |
| Chg. No. of employees % |
0%
|
-4%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.